Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00344461 · ClinicalTrials.gov registry record · Phase 4
A Two Year Study of the Clinical Efficacy of the Combination of Emtricitabine, Tenofovir, and Nevirapine
A Phase 4 study of HIV, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- Phase 4
- Development phase
- 54
- Enrollment target
- 1
- Study location
NCT00344461 is a Phase 4 study of HIV that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 54 participants, below the 440-participant average among 303 other HIV trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00344461, a Phase 4 study of HIV, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 54 participants
- Enrollment target
- 1
- Study location
Study Summary
Open label, two year study of the clinical efficacy of the combination of FTC, Tenofovir, and Nevirapine. Sixty HIV infected patients without previous exposure to antiretroviral therapy will be enrolled. Study will include a pharmacokinetic substudy to evaluate the interaction of FTC and Nevirapine. Truvada may be used.
Conditions Studied
Interventions
- DRUG Nevirapine, FTC, and Tenofovir
Study Locations (1)
Maryland
- University of Maryland, Institute of Human Virology - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2004-03 |
| Est. Completion | 2008-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00344461
The ClinicalTrials.gov registry entry for NCT00344461 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 440-participant average among 303 other HIV trials with a reported enrollment target (88% lower). The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV appearing as the primary indexed condition, and to 1 intervention - of which Nevirapine, FTC, and Tenofovir is the first listed.
NCT00344461 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00344461 about?
NCT00344461 is a clinical study titled "A Two Year Study of the Clinical Efficacy of the Combination of Emtricitabine, Tenofovir, and Nevirapine". Open label, two year study of the clinical efficacy of the combination of FTC, Tenofovir, and Nevirapine. Sixty HIV infected patients without previous exposure to antiretroviral therapy will be enrolled. Study will include a pharmacokinetic substudy to evaluate the interaction of FTC and Nevirapine....
What is the current status of trial NCT00344461?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 54 participants. The study started on 2004-03. Estimated completion is 2008-07.
What conditions does trial NCT00344461 study?
This clinical trial studies the following conditions: HIV.
What interventions are being tested in trial NCT00344461?
The interventions under investigation include: Nevirapine, FTC, and Tenofovir (DRUG).
Who is sponsoring clinical trial NCT00344461?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00344461 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessment of Metformin for Restoration of Immune Homeostasis in HIV+ and HIV- Individuals With a History of Injection Drug Use
RECRUITING · Phase 4
-
Integrated e-Health (Electronic Health) for HIV and Substance Use Disorders in Justice Involved Women
RECRUITING · Phase 4
-
Long-acting Cabotegravir Injectable Pre-exposure Prophylaxis for People Who Inject Drugs
RECRUITING · Phase 4
-
Implementation and Deliver of Lenacapavir for PrEP in a Community Pharmacy Setting
RECRUITING · Phase 4
-
Optimizing Evidence-based HIV Prevention Targeting People Who Inject Drugs on PrEP
RECRUITING · Phase 4
-
Immediate Initiation of Antiretroviral Therapy During "Hyperacute" HIV Infection
ACTIVE NOT RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.